Sustained Release Dexamethasone Anterior Chamber Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory eye drop regimens for cataract surgery are cumbersome, have low compliance, and marginally effective due to limited drug delivery to the eye, necessitating a more efficient and sustained anti-inflammatory therapy.
Innovation Solution
A short-term sustained release formulation of dexamethasone in triethyl acetyl citrate, injected into the anterior chamber of the eye, providing a high initial dose that tapers off quickly to minimize steroid-related adverse events, replacing the need for multiple eye drop applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory eye drops are used to treat inflammation after cataract surgery, then inflammation can be reduced, but patient compliance is poor and treatment duration is extended
Solution Approach 1:
The sustained-release formulation is prepared in advance with the drug encapsulated in biodegradable polymer matrices, allowing it to be administered as a single dose that automatically releases the drug over the required treatment period without requiring repeated patient applications
Solution Approach 2:
The implantable formulation releases dexamethasone automatically through diffusion and polymer degradation mechanisms, serving itself by maintaining therapeutic drug levels in the eye without requiring further patient intervention or compliance with dosing schedules
2Reliability
If anti-inflammatory eye drops are administered multiple times to maintain therapeutic levels, then inflammation can be controlled, but treatment time is extended and patient burden increases
Solution Approach 1:
The sustained-release formulation provides continuous drug delivery through controlled diffusion and polymer degradation, maintaining therapeutic dexamethasone levels in the eye throughout the entire treatment period without interruption or need for repeat administrations
Solution Approach 2:
The drug delivery system is pre-engineered with controlled release kinetics, incorporating the total required drug dose into a single implantable unit that automatically dispenses medication over the complete treatment duration, eliminating the need for extended treatment schedules
3Quantity of substance
If standard eye drop formulations are used, then drug can be delivered to the eye, but delivery efficiency is low with most dose lost
Solution Approach 1:
The formulation extracts the drug delivery system from the conventional eye drop format and replaces it with an implantable sustained-release device that bypasses the limitations of topical application, directly placing the medication reservoir within the eye to eliminate systemic loss and improve local drug availability
Solution Approach 2:
The biodegradable polymer matrix acts as an intermediary carrier that holds and gradually releases dexamethasone directly at the site of inflammation, mediating between the drug and the ocular tissues to ensure efficient local delivery without the losses associated with conventional eye drop administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This formulation effectively reduces inflammation post-cataract surgery, ensuring improved clinical outcomes and patient compliance by delivering dexamethasone for at least 3 days, with clinical trials showing anterior chamber cell counts below 2 within 30 days, outperforming standard eye drop therapies.
Implementation Method 1
a short-term sustained release formulation for sustained release of the anti-inflammatory drug dexamethasone... which formulation releases dexamethasone for at least 3 days
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery